Patents by Inventor Francis X. Tavares

Francis X. Tavares has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK INHIBITORS
    Publication number: 20240109906
    Abstract: Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 13, 2023
    Publication date: April 4, 2024
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
    Patent number: 11834411
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: December 5, 2023
    Assignee: NovaTarg, Inc.
    Inventors: Kenneth Batchelor, Jeffery E. Cobb, Kristjan S. Gudmundsson, Brad R. Henke, Francis X. Tavares
  • HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION
    Publication number: 20230364098
    Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 16, 2023
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
  • HSPC-sparing treatments for RB-positive abnormal cellular proliferation
    Patent number: 11654148
    Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: May 23, 2023
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
  • FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY
    Publication number: 20220213036
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Application
    Filed: January 18, 2022
    Publication date: July 7, 2022
    Inventors: Kenneth BATCHELOR, Jeffery E. COBB, Kristjan S. GUDMUNDSSON, Brad R. HENKE, Francis X. Tavares
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING BETA-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA
    Publication number: 20220125778
    Abstract: The present disclosure describes compounds and compositions that inhibit ?-glucuronidase activity, and methods for attenuating the side effects of one or more drugs and improving the efficacy of drugs by administration of selective ?-glucuronidase inhibitors.
    Type: Application
    Filed: March 6, 2020
    Publication date: April 28, 2022
    Inventors: Francis X. Tavares, Bret D. WALLACE, Ward PETERSON
  • Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
    Patent number: 11261157
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 1, 2022
    Assignee: NovaTarg, Inc.
    Inventors: Kenneth Batchelor, Jeffery E. Cobb, Kristjan S. Gudmundsson, Brad R. Henke, Francis X. Tavares
  • CDK INHIBITORS
    Publication number: 20210395259
    Abstract: Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: January 20, 2021
    Publication date: December 23, 2021
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay Copeland Strum
  • Small molecule c-Myc inhibitors
    Patent number: 11066398
    Abstract: This invention provides small molecule Myc-inhibitors. Also provided in the invention are therapeutic applications of these compounds for treating Myc-driven cancer and other related methods.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 20, 2021
    Assignees: The Scripps Research Institute, Sorrento Therapeutics, Inc.
    Inventors: Peter K. Vogt, Francis X. Tavares, Kim D. Janda
  • HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION
    Publication number: 20210213022
    Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Application
    Filed: February 22, 2021
    Publication date: July 15, 2021
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA
    Publication number: 20210094917
    Abstract: The present disclosure describes compounds and compositions that inhibit ?-glucuronidase activity, and methods for attenuating the side effects of one or more drugs and improving the efficacy of drugs by administration of selective ?-glucuronidase inhibitors.
    Type: Application
    Filed: September 7, 2018
    Publication date: April 1, 2021
    Inventors: Francis X. TAVARES, Bret D. WALLACE, Ward PETERSON
  • CDK inhibitors
    Patent number: 10927120
    Abstract: Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: February 23, 2021
    Assignee: GI Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay Copeland Strum
  • CDK INHIBITORS
    Publication number: 20200277300
    Abstract: Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: May 13, 2020
    Publication date: September 3, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay Copeland Strum
  • CDK inhibitors
    Patent number: 10696682
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 30, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay Copeland Strum
  • Transient protection of normal cells during chemotherapy
    Patent number: 10660896
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 26, 2020
    Assignee: GI Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
  • FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY
    Publication number: 20190345103
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Application
    Filed: December 7, 2017
    Publication date: November 14, 2019
    Inventors: Kenneth Batchelor, Jefferey E. Cobb, Kristjan S. Gudmundsson, Brad R. Henke, Francis X. Tavares
  • CDK INHIBITORS
    Publication number: 20190119292
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 25, 2019
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay Copeland Strum
  • CDK inhibitors
    Patent number: 10189850
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 29, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 10189849
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 29, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 10189851
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 29, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum